Kornimate/medical-research-clean huggingface dataset:
matrix metalloproteinases (mmps),neutrophil gelatinase-associated lipocalin (ngal) tissue and plasma levels and aneurysms

Conditions: MMPs and NGAL in Ruptured and Non-ruptured Aneurysms

Summary: an association between arterial aneurysms and matrix metalloproteinases (mmps) has been described previously. mmps regulate extracellular structural proteins and tissue remodeling. neutrophil gelatinase-associated lipocalin (ngal) is involved in the regulation of mmp activity. the aim of this work was to study the relationship between the levels of mmps and ngal and arterial aneurysms. in a multicenter, open label, parallel groups, prospective study, patients with aneurysmal disease were divided into two groups: group i (with ruptured aneurysm) and group ii (with non-ruptured aneurysm). healthy volunteer patients were also enrolled and represented the control group (group iii). the investigators enrolled 307 patients (group i: 107, group ii: 200) with arterial aneurysm: 49 popliteal, 31 common femoral, 2 superficial femoral, 29 common iliac artery, 3 common carotid and 193 abdominal aorta. finally, 11 healthy volunteer patients (9 males and 2 females, age range 40-70 year-old, median 56) were enrolled in group iii. elisa test and western blot analysis revealed greater levels of immunoreactive mmp-9 and ngal in all patients with ruptured aneurysms, both central and peripheral aneurysms, and in the aneurismal vessels. these results provide important advances in the understanding of the natural history of arterial aneurysms. mmps and ngal play a role in development of arterial aneurysms and they may represent molecular markers for the prevention of aneurysmal rupture

in the present study, the analysis of mmps levels in plasma and tissues in patients with aneurysmal lesions identified several patterns of protease activity. levels of both mmp-9 and ngal were increased in aneurismal vessels, while the patterns of mmp-9 and ngal expression was very high in all patients with ruptured aneurysm, both central and peripheral. these results show: 1) the chronic and degenerative nature of the aneurysmal lesion which is associated with increased levels of inflammatory proteinases, like mmp-9; 2) the apparent pivotal role of mmp-9 and ngal in the pathophysiologic processes which lead to the final stage of natural history of aneurysms; and 3) the ubiquitous distribution of mmp-9 and ngal. the pattern increased expression of mmp-9 and ngal appears to be specific for aneurysmal arteries and it is not dependent on the anatomic site of the lesion.

Eligibility criteria:
inclusion criteria: * patients with the diagnosis of arterial aneurysmal disease exclusion criteria: * history of cancer * hepatic failure * infectious or autoimmune diseases * patients requiring endovascular treatment.

Keywords: mmp ngal arterial aneurysms
efficacy of long-acting octreotide (sandostatin lar) in reducing portal pressure in patients with cirrhosis

Conditions: Cirrhosis; Portal Hypertension; Esophageal Varices

Summary: octreotide is used to control variceal bleeding. however, octreotide has to be given through the vein and is effective for less than two hours. in this study the investigators determined whether a long-acting preparation of octreotide (sandostatin lar)given as an intra-muscular injection every month could decrease portal pressure, and thus be used to prevent variceal bleeding in patients with cirrhosis.


Eligibility criteria:
inclusion criteria: 1. cirrhosis documented by biopsy, or suggested by characteristic features on abdominal imaging (nodular appearance, irregular contour) along with impaired synthetic liver function and thrombocytopenia and child turcotte pugh class a or b. 2. presence of small esophageal varices, defined as varices \< 5 mm in diameter, without red signs documented on endoscopy within 3 months of enrollment 3. age ≥ 18 years exclusion criteria: * pregnant, lactating or of child-bearing potential and not practicing acceptable method of birth control * allergic to sandostatin * high risk varices on endoscopy carried out within 3 months of assessment (large varices or red signs) * child turcotte pugh class c cirrhosis * hepatocellular carcinoma * evidence of ongoing alcohol or illicit drug abuse within 6 months of the study * serum creatinine greater than 2 mg/dl * platelet count below 50,000 per microliter * prothrombin time 4 seconds or more greater than control * human immunodeficiency virus (hiv) positive * symptomatic gallstones * previous history of upper gastrointestinal bleeding in the past 3 months, defined as hematemesis and/or melena * previous history of variceal bleeding * history of congestive heart failure , unstable angina, sustained ventricular tachycardia, or ventricular fibrillation * use of any investigational drug within 1 month prior to screening and * current use of beta blockers or long-acting nitrates, any other drug therapy known to have an influence on portal pressure (diuretics were allowed provided patients were on a stable dose for at least 30 days).

Keywords: portal hypertension varices cirrhosis octreotide somatostatin analog child pugh class a,b
immunogenicity, safety and tolerability of two doses of fluad-h5n1 influenza vaccine in adult and elderly subjects

Conditions: Influenza

Summary: this study is designed to evaluate the immunogenicity, safety and tolerability of 2 doses of fluad-h5n1 vaccine compared to 2 doses of trivalent, interpandemic fluad, each administered 3 weeks apart.


Eligibility criteria:
inclusion criteria: * healthy subjects 18 years of age who signed the informed consent exclusion criteria: * receipt of another investigational agent within 4 weeks * receipt of influenza vaccination for current season 2006/2007. * any acute disease or infection, history of neurological symptoms or signs, known or suspected impairment of immune function, any serious disease, bleeding diathesis * fever (defined as axillary temperature ³38.0°c) within 3 days (prior to visit 1) * pregnant or breastfeeding or females of childbearing potential who refuse to use an acceptable method of birth control * surgery planned during the study period * hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or polymyxin or any other component of the study vaccine * receipt of another vaccine within 3 weeks prior to visit 1 or planned vaccination within 3 weeks following the last study vaccination * history of (or current) drug or alcohol abuse * any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.

Keywords: influenza h5n1, pandemic
school inner city air study

Conditions: Viral Infection

Summary: the goal of this randomized clinical trial is to test the efficacy of high efficiency particulate air (hepa) cleaners in reducing respiratory viral exposure and infections in elementary school classrooms. classrooms will be randomized to active vs. sham hepa cleaners. the main questions it aims to answer are: * do classroom hepa cleaners reduce exposure to viruses? * do classroom hepa cleaners reduce student and teacher infections? * do classroom hepa cleaners reduce infections in family members?

classrooms from participating schools will be randomized to active vs. sham hepa cleaners. from enrolled classrooms, we will enroll students, teachers, and members of the household. we will collect the following: * longitudinal classroom air samples * longitudinal upper respiratory samples * longitudinal symptom surveys using the wisconsin upper respiratory symptom survey (wurss) viral testing on collected air and respiratory samples will be performed using digital polymerase chain reaction (dpcr).

Eligibility criteria:
inclusion criteria: children * grades k-5 (age 6-12 years) * attend one of the schools that the study team has permission to obtain classroom/school environmental samples * have no plans to move schools within the upcoming 12 months * subject and/or parent guardian must be able to understand and provide informed consent and also willing to participate in the study adults * adult (age 21 or older) parent, caretaker, or household member of child participating in this study, or teacher in classroom participating in study * able to understand and provide informed consent exclusion criteria: children * contraindication to or inability to participate in home self-collection of nasal swab samples * severe chronic diseases (e.g. cancer, genetic or congenital disorders interfering with mobility) * severe neurobehavioral, neurodevelopmental or psychiatric disorders requiring special assistance * families who do not speak english or spanish well enough to complete the survey questions, as validated versions in other languages are not available for all of the measures adults * contraindication to or inability to participate in home self-collection of nasal swab samples * severe chronic diseases (e.g. cancer, genetic or congenital disorders interfering with mobility) * severe neurobehavioral, neurodevelopmental or psychiatric disorders requiring special assistance * families who do not speak english or spanish well enough to complete the survey questions, as validated versions in other languages are not available for all of the measures
narrow band imaging versus white light for colonoscopy serrate lesions detection

Conditions: Colon Cancer; Colon Sessile Serrated Adenoma/Polyp

Summary: colorectal cancer (crc) is a leading cause of cancer death and its' incidence is rising in most european countries. colonoscopy has been shown to reduce crc incidence, however its effectiveness depends on the sensitivity to detect pre-malignant lesions. our aim is to evaluate narrow band imaging (nbi) during colonoscopy and serum mirnas as novel tools for the early detection of colonic sessile serrated lesions (ssl). the investigators will perform a multicenter-randomized-controlled-trial to study the role of nbi in ssl detection.


Eligibility criteria:
inclusion criteria: * patients scheduled for elective colonoscopies exclusion criteria: * known polyposis syndromes * primary sclerosing cholangitis * inflammatory bowel disease * personal colorectal cancer history
post-operative pain reduction

Conditions: Effects of the Elements

Summary: recruited patients with necrotic pulp after application of conventional calcium hydroxide paste are assigned to group, calcium hydroxide nanoparticle group and combined calcium hydroxide with silver nanoparticle group and record postoperative pain afterwards.

the investigator will recruit patients who are found eligible to the criteria, conventional calcium hydroxide paste , calcium hydroxide nanoparticle and combined calcium hydroxide with silver nanoparticle . after 48 hours, patients will be randomly assigned to removal of intracanal medication after the visit, patients will be asked to record post operative pain by numerical rating scale)in a given sheet

Eligibility criteria:
inclusion criteria: * • medically free patients. * patient's age between 25-50 years. * sex includes both male and female. * radiographic evidence of a periapical radiolucent lesion associated with tooth. * necrotic pulp as indicated by thermal pulp testing. * no history of previous endodontic treatment of the tooth. exclusion criteria: * • teeth with unfavorable conditions for rubber-dam application. * teeth with acute periapical abscesses swelling. * medically compromised patients. * immature teeth with open apices. * multi rooted teeth. * pregnant women.
quantification of ketosis after intake of coconut oil and caprylic acid-with and without glucose-after a 12-hour fast

Conditions: Aged

Summary: in a cross-over design, 15 participants, age 65-75, will be tested in six different arms in a randomised order. after a 12-hour fast participants will be served 2.5 dl coffee with 15 g cream + 30-50 g of different fatty acids, with or without 50 g glucose. blood ketones and other biomarkers will be measured during 4 hours.

in the metabolic state ketosis, beta-hydroxybutyrate (bhb) and acetoacetate are synthesised from fatty acids in the liver, resulting in higher circulating levels. ketosis can be induced by fasting or adherence to a low-carb-high-fat diet, but also by intake of-at least some-medium-chain-triglycerides (mct). mct are built from fatty acids with a chain of 6-12 carbon atoms. caprylic acid (c8) is well known to be ketogenic, but the effect of lauric acid (c12)-constituting about 50% of coconut oil-is less clear. the aim of this study is to assess ketosis, as a combined effect of an extended overnight fast, and intake of coconut oil or c8, and to study how ketosis is affected by simultaneous glucose intake. sunflower oil is used as control, expected to not break fasting ketosis, although not being ketogenic in itself. some sunflower oil is also added to c8 to make that arm isocaloric with coconut oil, with a roughly similar proportion of mct. coffee with cream will be used as a vehicle, and although coffee has been reported to be mildly ketogenic, this effect is expected to be negligible and equally distributed between arms.

Eligibility criteria:
inclusion criteria: * daily consumption of coffee * written informed consent exclusion criteria: * smoker * weight \<50 kg * diagnosed diabetes * history of heart disease * history of disease related to internal organs or metabolism * experience of "sensitive gut", or known intolerance to the test ingredients * medication expected to affect glucose- or lipid-metabolism * fasting during study or one month before * high intensity physical activity \> 3 times/week * dementia * severe psychiatric conditions * hb\<125 g/l * participation in other lifestyle intervention last 6 months
8% sulphur-aloe vera soap as an adjuvant treatment for pityriasis versicolor

Conditions: Pityriasis Versicolor

Summary: pityriasis versicolor (pv) is a superficial, mild, often chronic recurring infection of the skin caused by malassezia species which is characterized by the formation of hypopigmented, hyperpigmented and/or erythematous macules. it commonly occurs on the trunk and proximal extremities, but can also be found on the entire body. diagnosis of pv established based on clinical features and microscopic examination with potassium hydroxide. the goals of pv treatment are: to eradicate the hyphae, disappearance of clinical signs and symptoms, to lessen recurrences, and improve patient's quality of life. topical antifungal remains first line therapy and search for an ideal topical agent of pv continue. various studies reported combining more than one topical agents can increase the efficacy, thus result in faster mycological cure.

pityriasis versicolor commonly has extensive and irregular pattern/distribution on the body. therefore, topical antifungal such as ketoconazole, usually given in shampoo or solution form to cover large surface area. many studies reported adverse effects of ketoconazole shampoo including pruritus, dry skin, and allergic contact dermatitis. non-spesific keratolytic agent, such as sulphur, used for pv work by desquamation of the entire superficial skin layer and eliminating the fungi in the process. it also could enhance the penetration of ketoconazole into the stratum corneum, increasing its potency. aloe vera (a. vera) contains acetylated mannan that acts as humectant and increase water content in stratum corneum. the combination of sulphur and a. vera in form of a soap as adjuvant to ketoconazole shampoo potentially will result in synergistic effect, faster mycological cure, and less adverse effects. there are limited data of sulphur and a.vera soap as an adjuvant pv treatment to ketoconazole shampoo. as a result of limited data, our trial is looked forward to assess the efficacy and adverse effect of sulphur and a.vera soap as an adjuvant pv treatment to ketoconazole shampoo.

Eligibility criteria:
inclusion criteria: 1. male or female 2. age 18-65 years 3. diagnosed as pv based on clinical features, microscopic examination using 10% potassium hydroxide, and wood's lamp exclusion criteria: 1. pregnant or lactating women 2. pv with concurrent skin conditions (dermatitis or skin lesions in form of vesicles or blister or pustules or erosions or excoriation) with body surface area \>30% 3. use of topical antifungal and/or corticosteroid 14 days prior to study entry 4. use of systemic antifungal and/or corticosteroid 30 days prior to study entry 5. history of allergy to shampoo or soap containing ketoconazole, sodium lauryl sulphate, sulphur, a. vera, charcoal powder, glycerin, or perfume.
the efficacy and safety of nerve-sparing radical hysterectomy in cervical cancer

Conditions: Cervical Cancer

Summary: to develope nerve sparing radical hysterectomy for treatment of cervical cancer to minimize the complication of radical hysterectomy and to maximize quality of life and to evaluate the feasibility and efficacy by prospective randomized trial.


Eligibility criteria:
inclusion criteria: * histologically diagnosed cervical cancer * figo stage ia2-iia * diameter of tumor is less than 4cm on exam * one of hitological type written below squamous cell carcinoma, adenocarcinoma, adenosquamous cell carcinoma * age between 18-70 * performance status; gog 0-1 * normal hematological, hepatic, nephrologic function wbc ≥ 4000 cells/mm3 platelet ≥ 100,000 /mm3 hemoglobin ≥ 8.0 gm/dl serum creatinin ≤ 1.3 mg/dl serum bilirubin ≤ 1.5 mg/dl sbot/sgpt and alkaline phoaphatase \< normal x 3 * patient with informed consent exclusion creteria: * small cell carcinoma * unable to perform surgery because of severe underlying medical disease severe heart disease, congestive heart failure/severe pulmonary disease, pulmonary failure/ active bacterial infectio which needs non oral antibiotic therapy/ associated with other severe medical diseases * prior chemotherapy or radiotherapy * severe bladder funtion abnormality * double primary malignant tumor * psychiatric problems * pregnant or breast feeding status * legally unable to participate clinical trial * when there is a doctor's decision that patient is unable to participate clinical trial

Keywords: cervical cancer nerve sparing radical hysterectomy
a safety and efficacy study of daikenchuto (tu-100) to treat crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to determine whether daikenchuto(tu-100)is effective in the treatment of crohn's disease.

crohn's disease, a chronic condition resulting in inflammation of the gastrointestinal tract (gi), causes a person to experience persistent symptoms of inflammatory bowel disease, including abdominal pain, nausea, vomiting, rectal bleeding, diarrhea, and constipation, with infrequent bowel movements that are at times accompanied by a sensation of incomplete emptying after having a bowel movement. tsumura's tu-100 is a modern herbal product that has been approved as a prescription drug in japan. several lines of evidence indicate that tu-100 attenuates intestinal inflammation in crohn's disease by increasing intestinal blood flow and stimulating a protective lining of intestinal mucus which produces an anti-inflammatory effect. tu-100 may attenuate pathological changes in the intestine and reduce symptoms in patients with crohn's disease.

Eligibility criteria:
inclusion criteria: * provide written informed consent * ability to orally ingest study medication * male or female between 18 to 75 inclusive * diagnosed with crohn's disease for at least 3 months * cdai score of 220-300 at screening * sexually active participants of childbearing potential must agree to birth control * no clinically significant conditions which the doctor would feel exclusionary * stable medication (including probiotics) exclusion criteria: * history of any bowel condition that may interfere with the evaluation of the study drug * positive stool cultures * currently pregnant or lactating * receiving total parenteral nutrition * history of alcohol or drug abuse within one year * history of malignancy within 5 years * current use of anticholinergic agents, antidepressants during the study, warfarin, prokinetics, antipsychotic agents or narcotic analgesics * treatment with anti-tnf agents 12 weeks before screening * treatment with corticosteroids four weeks prior to screening * treatment with cyclosporine or tacrolimus eight weeks prior to screening * presence of a poorly controlled medical condition * history of allergic reaction to ginseng, ginger or sichuan pepper * any use of supplemental ginger, ginseng and sichuan powder 2 weeks prior to and through course of the trial * current use of any of the following herbal medications: boswellia, cat's claw (uncaria tomentosa), cayenne pepper, echinacea, horsetail (equisetum), hops, lady's mantle (alchemilla), marshmallow root (althaea), slippery elm (ulmus rubra) turmeric and white willow (salix alba) * history of celiac disease * current diagnosis of lactose intolerance * history of any other investigational medication within 30 days of enrolling in study * unsuitability as determined by the study doctor

Keywords: crohn's disease natural herbal kampo inflammatory bowel disease adult ages 18 to 75 male and female subjects
α-lipoic acid (ala), magnesium, vitamin b6 and vitamin d and risk factor for pre-term birth

Conditions: Cervical Shortening; Preterm Birth

Summary: effects of oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin b6 and vitamin d in tablets of 1,2 g administered daily to women presenting risk factors for preterm birth (ptb). the aim is to reduce the rate of short cervix at 19-21 weeks of gestational age and consequently reduce the occurrence of ptb.

the physiological course of pregnancy can be threatened by the onset of rhythmic and progressive uterine contractions, associated with a shortening and dilation of the cervix. these modifications occur as a consequence of inflammatory processes that involve important changes in the extracellular matrix of connective tissues. for this reason, in the event of a threat of preterm birth, the appropriate tocolytic therapies should be associated with interventions able to counteract morphological changes in the uterine cervix. women presenting high or low bmi, presence of uterine myomas, metrorrhagia during the first trimester and hypertensive disorders are at risk for ptb. current management practices remain profoundly various, without a therapeutic tocolytic strategy, especially because most of the first-line tocolytic drugs used present important side effects \[8\]. it is to be assessed whether a supplementation during pregnancy with minerals, vitamins, anti-inflammatory and anti-oxidant agents can avoid ptb in women with risk factors. ala may interact synergistically with magnesium, vitamin b6 and vitamin d, limiting some of the main factors related to the risk of preterm delivery - probably via the inhibition of nuclear factor k beta (nf-kb)-signaling pathway - and reducing therefore the rate of uterine contractions. moreover, the administration of ala, magnesium, vitamin b6 and vitamin d have been demonstrated to be safe in pregnancy. the aim of the present study is to evaluate whether pregnant women presenting risk factors for ptb, treated with a combination of ala, magnesium, vitamin 6 and vitamin d from 11-14 weeks of gestational age, until delivery, could present a reduced rate of cervical shortening measured by transvaginal ultrasound (tvs) at 11-14 weeks and 19-21 weeks of gestational age.

Eligibility criteria:
inclusion criteria: 1. nulliparous, 2. previous history of preterm birth, 3. age between 18 - 41 years, 4. 11-14 weeks of gestation, 5. bmi \< 18 kg/m2 or ≥ 30 kg/m2, 6. uterine myoma, 7. hypertensive disorders either chronic or induced by the pregnancy exclusion criteria: 1. pprom, 2. cervical dilation ≥ 1 cm

Keywords: alpha-lipoic acid vitamin d cervical shortening pretermbirth food supplement